Experience

• 

  Bristol-myers squibb

  Jan 1997 - Jan 2005

  Provided full financial support to the Biologics Global Full Development team in pre-launch phase of 2 biologics therapies. Developed strategic plans, operating budgets, sales forecasts, ROI analysis, manufacturing analysis, pricing scenarios and investment strategies to maximize the development and commercialization of the products. Partnered with multiple stakeholders including Marketing and Medical leaders to provide input to management on key issues, contingency plans and accuracy of financial forecasts. Show less

  • Senior Manager, Financial Analysis, Biologics

    Jan 2003 - Jan 2005

  • Manager, Financial Analysis Pravachol

    Jan 2001 - Jan 2003

  • Principal Financial Analyst, Plavix

    Jan 2000 - Jan 2001

  • Principal Financial Analyst, US Pharm HQ

    Jan 1997 - Jan 2000
• 

  Bristol myers squibb

  Jan 2006 - Jan 2011

  Assoc director, finance us immunoscience division

  CFO of $600M Pharmaceutical business based in Princeton, NJ specializing in biologics therapies. Member of Management Board with responsibility for all financial activity including budgets, projections, and strategic planning. Provide decision analysis support on key issues including business performance trends, pricing analysis and investment decisions.

• 

  Rutgers university

  Jun 2011 - Apr 2012

  Office of budget management

  Prepared, managed, and monitored the University’s $2B operating budget. Developed and enforced budget policies and procedures for all University departments. Controlled all aspects of the University’s budget cycles.

• 

  Sandoz

  Apr 2012 - now

  Provide full financial support to the $400m US pharmaceutical business specializing in biosimilar therapies. Responsibility for all financial activities including budgets, projections, strategic planning and monthly closings. Worked with leadership to develop net sales and operating income targets. Completed fact based analysis of budget trends/variances• Created gross-to-net accrual analysis to determine accurate Medicaid and Managed Care rebate accruals generating correct accrual reserves in excess of $80m.• Developed unique reporting structure for the division to develop accurate product P&L’s previously unavailable.• Managed various forecast cycles and month end close processes ensuring accurate and timely reporting including the analysis of financial performance versus targets.• Authored a five-year Strategic Plan that presented a well-defined roadmap towards of goal of $1B in sales within the next two years.• Received Novartis Global Finance Award and Sandoz Finance Excellence Award for the successful launch of Copaxone generic product, and the successful launch of the 1st biosimilar in US Show less

  • Director Business Planning and Analysis

    May 2019 - now

  • Director Finance Net Working Capital

    Jun 2017 - May 2019

  • Associate Director, Business Planning & Analysis, US Biosimilars

    Oct 2014 - Jun 2017

  • Manager, Business Planning & Analysis, BioPharm

    Apr 2012 - Sept 2014